How Can Aesthetic Practitioners Evaluate Hyperpigmentation Depth In Fitzpatrick Phototypes Iv–Vi To Determine The Appropriate Laser Protocol For Dermal Dyschromia? Master Safe Nd:yag Treatment

Depth assessment must precede laser selection. In Fitzpatrick phototypes IV–VI, practitioners should combine clinical history, visual examination, dermoscopy, and—when appropriate—Wood’s lamp findings to classify pigmentation as predominantly epidermal, dermal, or mixed. Epidermal pigment may be approached with topical therapy or superficial procedures, whereas confirmed dermal dyschromia may be considered for conservative, staged treatment with a long-pulsed or Q-switched 1064 nm Nd:YAG, subject to diagnosis, test-spot results, and local clinical protocols.

Wood’s lamp is a useful screening tool, not a standalone depth test. Fluorescence that becomes more apparent suggests superficial epidermal pigment; absent or minimal fluorescence raises suspicion for dermal pigment, but this distinction is less reliable in darker skin and in mixed lesions. Treatment should therefore be based on the complete clinical picture and a cautious test spot—not on Wood’s lamp findings alone.

Why Depth Assessment Matters in Phototypes IV–VI

Epidermal melanin increases treatment risk

Fitzpatrick IV–VI skin contains substantial epidermal melanin, which competes with the target pigment for laser energy. Excessive fluence, short pulse delivery, pulse stacking, or inadequate cooling can cause epidermal injury and trigger post-inflammatory hyperpigmentation (PIH) or hypopigmentation.

Dermal pigment is not automatically a laser indication

“Dermal” describes pigment location, not a single disease. Dermal melanophages, nevus of Ota-like lesions, post-inflammatory pigment incontinence, melasma, and other conditions can appear similar but respond differently to treatment.

A diagnosis should be established before selecting a pigment laser. Any lesion that is atypical, changing, unilateral without a clear explanation, indurated, symptomatic, or diagnostically uncertain may require dermatologic assessment and, in selected cases, biopsy.

How to Estimate Pigment Depth

Start with history and morphology

Document the onset, precipitating inflammation or trauma, hormonal factors, medication exposure, prior procedures, recurrence pattern, and previous response to treatment.

Clinically, epidermal pigment is often tan to brown and may have a relatively superficial, sharply visible appearance. Dermal or dermal-predominant pigment is more often blue-gray, slate-gray, or gray-brown, reflecting optical scattering and deeper pigment.

These color patterns are suggestive rather than definitive. Mixed epidermal–dermal pigmentation is common, particularly after inflammation or in melasma.

Use dermoscopy as a complementary examination

Dermoscopy can help distinguish superficial brown pigment from gray-blue structures that suggest dermal melanophages or deeper pigment. It also helps identify vascular, inflammatory, or structural features that may make a pigment-only treatment inappropriate.

The examination should be documented with standardized photography so that changes can be compared objectively over time.

Use Wood’s lamp cautiously

A Wood’s lamp can make some superficial epidermal pigment appear more conspicuous, while dermal pigment generally shows little or no accentuation. However, the test has important limitations in phototypes IV–VI because baseline epidermal melanin can reduce contrast and obscure the result.

A positive fluorescence supports, but does not prove, epidermal predominance. A negative result does not prove dermal pigment; it may reflect mixed disease, inadequate examination conditions, or limited test sensitivity.

Consider biopsy when the diagnosis remains uncertain

A biopsy is not required for every dyschromia, but it is appropriate when the diagnosis will materially change management or when the lesion has atypical features. Histology can distinguish epidermal pigment, dermal melanophages, melanocytic lesions, lichenoid inflammation, and other causes of dyschromia.

Matching Depth and Diagnosis to Treatment

Predominantly epidermal dyschromia

Superficial pigment is usually managed first with removal of the cause, photoprotection, and topical therapy. Depending on the diagnosis and skin tolerance, clinicians may consider tyrosinase-inhibiting agents or carefully selected superficial chemical peels.

Laser treatment is not automatically superior. In phototypes IV–VI, unnecessary epidermal heating may create more inflammation and pigment than it removes.

Predominantly dermal dyschromia

Confirmed dermal pigment may be considered for a pigment-targeting laser, commonly a 1064 nm Nd:YAG platform. Its longer wavelength has lower absorption by superficial melanin than shorter visible wavelengths and can reach deeper targets with less epidermal competition.

The exact platform and mode matter. Q-switched and picosecond devices, for example, deliver different pulse characteristics, and the appropriate choice depends on the diagnosis, lesion depth, tissue response, and operator experience.

Mixed dyschromia

Mixed lesions require a staged strategy. Treating the dermal component aggressively while ignoring active epidermal inflammation, melasma, or ongoing ultraviolet and visible-light exposure increases the chance of recurrence and PIH.

A practical approach is to stabilize the epidermal component first, then reassess whether a deeper laser intervention is still necessary.

Building a Safer Protocol for Darker Skin

Stabilize the skin before treatment

Do not laser actively inflamed, irritated, recently tanned, or unstable skin. Identify and manage dermatitis, acne, friction, hair-removal irritation, or other triggers that could amplify melanogenesis.

For patients with a strong PIH history, clinicians may use a supervised preconditioning program with topical pigment-suppressing agents. Hydroquinone, retinoids, azelaic acid, kojic acid, or other agents may be appropriate in selected patients, but irritation itself can worsen dyschromia and these treatments require individualized prescribing and monitoring.

Use strict photoprotection

Broad-spectrum sunscreen and avoidance of intense ultraviolet exposure are essential before and after treatment. For melasma-prone or visible-light-sensitive patients, protection that includes visible-light coverage may be particularly relevant.

Photoprotection is not merely aftercare; it is part of determining whether the patient is ready for treatment.

Begin conservatively

For phototypes IV–VI, initial treatment should generally favor:

Lower starting fluence than would be used in lighter phototypes.
Conservative treatment density and spot overlap.
Appropriate pulse duration for the device and target.
Active epidermal cooling before, during, and after delivery.
Multiple staged sessions rather than one aggressive correction.
Strict avoidance of pulse stacking or uncontrolled heat accumulation.

There is no universally safe fluence based on Fitzpatrick type alone. Device design, spot size, pulse width, lesion diagnosis, anatomic site, and prior response all affect risk.

Perform a test spot

A test spot in a representative but discreet area is one of the most important safeguards. Assess immediate response and delayed effects, including erythema, edema, crusting, hypopigmentation, and PIH, before treating a larger area.

The test spot should be interpreted over an appropriate observation period rather than judged only by immediate pigment whitening or darkening.

Recognizing When the 1064 nm Nd:YAG Is Appropriate

Situations that support consideration

A 1064 nm Nd:YAG may be reasonable when:

The diagnosis is established.
Pigment is clinically and dermoscopically dermal-predominant.
Epidermal disease and inflammation are controlled.
The patient understands that improvement may require several sessions.
A conservative test spot has shown acceptable healing.

Situations requiring caution

Extra caution is warranted with active melasma, recent tanning, a history of severe PIH, ongoing dermatitis, uncertain diagnosis, or lesions with atypical clinical features.

The wavelength alone does not make treatment safe. Excessive fluence, repeated passes, or pulse stacking with a 1064 nm device can still cause thermal injury and dyspigmentation.

Understanding the Trade-offs

Lower energy improves safety but may slow clearance

Conservative parameters reduce the probability of epidermal injury but may produce slower or incomplete pigment clearance. Patients should be counseled that staged treatment is often safer than pursuing rapid correction.

Dermal pigment may respond incompletely

Dermal melanophages and deeper chromophore distributions can be difficult to clear. A lack of response should prompt diagnostic reassessment rather than automatic escalation of energy.

Repeated low-fluence treatment is not risk-free

Multiple sessions can still accumulate inflammation and provoke PIH, particularly if intervals are too short or the skin has not fully recovered. Treatment should be repeated only after the previous session has healed and pigment behavior is understood.

Topical suppressants can irritate

Hydroquinone and retinoids may reduce melanogenesis in appropriate patients, but irritant dermatitis can itself trigger PIH. Use should be supervised, and a patient should not be treated through significant erythema, burning, or peeling.

How to Apply This to Your Project

The following framework keeps depth assessment, diagnosis, and risk management connected:

If your primary focus is epidermal pigmentation: Confirm the superficial or mixed pattern, control triggers, use topical therapy and photoprotection first, and avoid reflexive laser treatment.
If your primary focus is confirmed dermal dyschromia: Consider a conservative, test-spotted 1064 nm Nd:YAG protocol with staged sessions, active cooling, and careful documentation.
If your primary focus is minimizing PIH: Stabilize the skin, use individualized preconditioning when appropriate, start conservatively, avoid pulse stacking, and provide rigorous ultraviolet and visible-light protection.
If your primary focus is diagnostic certainty: Combine history, morphology, dermoscopy, and cautious Wood’s lamp interpretation, referring for specialist assessment or biopsy when the diagnosis is unclear.
If your primary focus is treatment optimization: Escalate only after delayed healing and pigment response have been reviewed; do not use higher fluence to compensate for an uncertain diagnosis.

Accurate diagnosis and conservative testing—not Fitzpatrick classification or Wood’s lamp findings alone—should determine the laser plan.

Summary Table:

Assessment Method	What It Shows	Limitations in Phototypes IV–VI
Clinical History & Morphology	Tan/brown suggests epidermal; blue-gray suggests dermal	Color is suggestive, not definitive; mixed lesions common
Dermoscopy	Distinguishes superficial brown from gray-blue dermal melanophages	Requires training; may not detect deep pigment
Wood's Lamp	Accentuates epidermal pigment; dermal shows little change	Less reliable in darker skin; negative result doesn't rule out dermal
Biopsy	Definitive diagnosis of pigment location and type	Invasive; reserved for uncertain or atypical cases

For advanced, safe laser solutions tailored to darker skin types, trust BELIS. Our portfolio includes the latest 1064 nm Nd:YAG, Q-switched, and picosecond lasers, plus IPL and PDT devices, designed to achieve optimal results while minimizing PIH risk. Our expert team offers comprehensive training and support to ensure you deliver the highest standard of care. Contact us today to learn how BELIS can elevate your practice and expand your treatment offerings! Get in touch with our specialists.